Aquinox’s bladder pain drug misses the mark in Phase II

Damian Garde

Aquinox's lead failed its main goal in a II trial on syndrome, but the company believes its oral treatment showed enough to promise to merit further study.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS